Fintel reports that on May 27, 2026, Needham upgraded their outlook for ICU Medical (NasdaqGS:ICUI) from Hold to Buy.
Analyst Price Forecast Suggests 31.04% Upside
As of May 14, 2026, the average one-year price target for ICU Medical is $176.87/share. The forecasts range from a low of $161.60 to a high of $210.00. The average price target represents an increase of 31.04% from its latest reported closing price of $134.97 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for ICU Medical is 2,590MM, an increase of 20.09%. The projected annual non-GAAP EPS is 15.03.
What is the Fund Sentiment?
There are 288 funds or institutions reporting positions in ICU Medical. This is an decrease of 231 owner(s) or 44.51% in the last quarter. Average portfolio weight of all funds dedicated to ICUI is 0.06%, an increase of 64.74%. Total shares owned by institutions decreased in the last three months by 17.59% to 28,042K shares. 
The put/call ratio of ICUI is 0.08, indicating a bullish outlook.
What are Other Shareholders Doing?
Janus Henderson Group holds 2,676K shares representing 10.71% ownership of the company. In its prior filing, the firm reported owning 2,577K shares , representing an increase of 3.71%. The firm decreased its portfolio allocation in ICUI by 61.05% over the last quarter.
Vanguard Portfolio Management holds 1,438K shares representing 5.75% ownership of the company.
Fuller & Thaler Asset Management holds 1,221K shares representing 4.88% ownership of the company. In its prior filing, the firm reported owning 1,266K shares , representing a decrease of 3.71%. The firm decreased its portfolio allocation in ICUI by 13.00% over the last quarter.
Vanguard Capital Management holds 1,112K shares representing 4.45% ownership of the company.
Schroder Investment Management Group holds 701K shares representing 2.81% ownership of the company. In its prior filing, the firm reported owning 765K shares , representing a decrease of 9.14%. The firm decreased its portfolio allocation in ICUI by 14.09% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
